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Abstract: Alcoholism is one of the most common diseases that can lead to the development of several
chronic diseases including steatosis, and cognitive dysfunction. Statins are lipid-lowering drugs that
are commonly prescribed for patients with fatty liver diseases; however, the exact effect of statins
on cognitive function is still not fully understood. In the present study, we have investigated the
molecular and microscopic basis of cognitive impairment induced by alcohol and/or Atorvastatin
(ATOR) administration to male Wistar albino rats and explored the possible protective effect of
acetylsalicylic acid (ASA). The biochemical analysis indicated that either alcohol or ATOR or together
in combination produced a significant increase in the nucleotide-binding domain–like receptor
3 (NLRP3), interleukin-1β (IL-1β) miRNA155 expression levels in the frontal cortex of the brain
tissue. The histological and morphometric analysis showed signs of degeneration in the neurons
and the glial cells with aggregations of inflammatory cells and a decrease in the mean thickness of
the frontal cortex. Immunohistochemical analysis showed a significant increase in the caspase-8
immunoreaction in the neurons and glial cells of the frontal cortex. Interestingly, administration
of ASA reversed the deleterious effect of the alcohol and ATOR intake and improved the cognitive
function as indicated by biochemical and histological analysis. ASA significantly decreased the
expression levels of miRNA155, NLRP3, and IL1B, and produced a significant decrease in caspase-8
immunoreaction in the neurons and glial cells of the frontal cortex with a reduction in the process of
neuroinflammation and neuronal damage. To further investigate these findings, we have performed
an extensive molecular docking study to investigate the binding affinity of ASA to the binding
pockets of the NLRP3 protein. Our results indicated that ASA has high binding scores toward the
active sites of the NLRP3 NACHT domain with the ability to bind to the NLRP3 pockets by a set of

Pharmaceutics 2022, 14, 529. https://doi.org/10.3390/pharmaceutics14030529

https://www.mdpi.com/journal/pharmaceutics

Pharmaceutics 2022, 14, 529

2 of 26

hydrophilic and hydrophobic interactions. Taken together, the present study highlights the protective
pharmacological effect of ASA to attenuate the deleterious effect of alcohol intake and long term
ATOR therapy on the cognitive function via targeting miRNA155 and NLRP3 proteins.
Keywords: alcoholism; statins; atorvastatin; acetylsalicylic acid; histopathology; miRNA155; NLRP3
inflammasomes; molecular docking

1. Introduction
With over 2.5 million deaths annually worldwide, alcohol abuse causes a myriad
of serious health consequences leading to physical and mental damage [1]. Alcohol is
absorbed in the gastrointestinal tract, and transferred to the liver and lungs where it is metabolized leading to direct toxicity, an accumulation of fatty acid, ethyl esters and oxidative
stress [2]. Furthermore, alcohol can impact blood pressure giving rise to cardiovascular
disease, coronary heart disease, stroke, peripheral arterial disease, and cardiomyopathy [3].
Chronic alcohol abuse might affect the lung parenchyma increasing the incidence of acute
respiratory disease [4]. Alcoholic fatty liver (steatosis), alcoholic hepatitis, and fibrosis
are associated with the progression of liver cirrhosis, with the highest risk in alcoholism.
Chronic alcoholism is also implicated with impaired cognitive function and structural
abnormalities in different brain areas [5]. Long-term alcohol intake results in neuroinflammation and neurodegeneration in humans as well as animal models [6]. Several studies
reported that the prefrontal cortex, which plays a vital role in cognitive functions, is more
vulnerable to alcohol-related brain damage [7], while steatosis occurs in almost all individuals who excessively consume alcohol. Statins are lipid-lowering drugs that act as
competitive inhibitors for 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA),
a key enzyme in the synthesis of cholesterol. Statins are the first drug line for treating lipid
disorders and are commonly prescribed for patients with alcoholic and non-alcoholic fatty
liver diseases to help in the reduction of atherosclerotic cardiovascular events by reducing
low-density lipoprotein cholesterol [8]. They are also recommended for liver cirrhosis to
reduce disease complications and the mortality rate [9]. Although statins are prevalent
drugs, they have several reported side effects such as, muscle complaints, neurological and
neurocognitive effects, renal toxicity, and hepatotoxicity [10]. Among the known statins,
Atorvastatin (ATOR), a synthetic lipophilic statin, can passively diffuse across the cell
membrane which decreases its hepatoselectivity [10].
Yang et al. recently reported that chronic alcohol intake upregulates the expression
of proinflammatory interleukin (IL)-1β cytokine (IL-1β) and nucleotide-binding domain–
like receptor3 (NLRP3) in different brain areas [11]. NLRP3 is a subcellular multiprotein
complex that is expressed in the central nervous system (CNS) and it is responsible for
neuroinflammation and associated brain disease. NLRP3 is an inflammasome-forming
NLR that has been involved in the pathogenesis of many inflammatory diseases [12]. The
NLRP3 inflammasome is a critical component of the innate immune system that mediates
caspase-1 activation and the secretion of proinflammatory cytokines: IL-1β and IL-18 in
response to cellular damage [13]. Activation of NLRP3 inflammasomes by caspase-8, an
apoptotic caspase, plays a crucial role in regulating the inflammasome activation and
pro-inflammatory cytokine levels [13]. Further, stimulation of NLRP3 causes the induction
of the apoptosis-associated speck-like protein containing a C-terminal caspase recruitment
domain (ASC), which activates the cleavage of pro-caspase-1 into its cleaved form, caspase1, which in consequence plays a role in the maturation of IL-1β into its active form [14].
Recently, it was shown that caspase-8 modulates the NLRP3-dependent caspase-1 signaling
cascades that initiate IL-1β production and pyroptotic cell death [15].
Cognitive dysfunction has been considered as a potential severe consequence of alcohol abuse. Alcohol exposure induces the dysregulation of microRNAs (miRNAs) of the
brain tissues. In human post-mortem brain samples, robust changes in miRNA expression
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have been reported in the prefrontal cortex of subjects with a history of chronic alcohol
abuse [16,17]. Among the different brain miRNAs, miRNA-155 is the most prominent
miRNA that is significantly upregulated in the brain of chronic alcoholism with possible
implications for inflammatory conditions and cognitive dysfunction [18,19]. miRNA155 is
a proinflammatory intermediary of the CNS that is stimulated within macrophages and
microglia [20]. In an interesting study, Lippai et al. showed that alcohol abuse stimulates
neuroinflammation in the cerebellum by mediating miR-155 in a TLR4-dependent manner [21]. Further, it was shown that miRNA155 enhances the expression of NLRP3-IL-1β
which has been involved in the pathogenesis of alcohol-induced neuroinflammation [21].
Interestingly, several studies have demonstrated that ATOR can also affect the NLRP3
inflammasomes and IL-1β expression [22–24]. Indeed, the effect of ATOR (statins) on
cognitive function has not been fully investigated. It is well known that statins induce
the suppression of cholesterol synthesis which could cause cognitive impairment by affecting cholesterol levels locally in the CNS [25]. Although the association of miRNA155
and NLRP3 to cognitive function in alcoholism has been recently explored, the correlation between the miRNA155–NLRP3 pathway and alcohol-induced cognitive dysfunction
associated with ATOR treatment is still not fully understood.
Acetylsalicylic acid (ASA, aspirin) is a non-steroidal anti-inflammatory drug that is
usually used as an analgesic, anti-pyretic, and anti-inflammatory drug. With numerous
benefits over other non-steroidal drugs, ASA decreases the risk of CVD by decreasing
blood clot formation and inhibiting platelets’ activation through its antithrombotic properties [26]. Preclinical models have suggested that ASA may decrease neuroinflammation
and oxidative stress in the CNS. The pleiotropic mechanisms of action of ASA could aid in
the prevention of cognitive dementia [27]. Recent studies showed that a low dose of ASA
alleviates the hepatotoxic effects of alcohol by modulating the NLRP3 inflammasome pathway and IL-1β [28,29]. Further studies have showed that ASA improves the endothelial
dysfunction by targeting NLRP3 inflammasome through the ROS/TXNIP pathway [26].
These results suggest that ASA could be applied for the treatment of cognitive dysfunction
by targeting the NLRP3-IL-1β pathway.
Encouraged by the above-mentioned facts, the presented study aimed at exploring
the role of the miRNA155–NLRP3 inflammasomes pathway on the cognitive dysfunction
induced by chronic alcohol ingestion and/or ATOR treatment. Further, we investigated
the possible role of ASA in targeting this pathway via biochemical, histopathological,
immunohistochemical, and in silico molecular modelling studies.
2. Materials and Methods
2.1. Animals and Grouping
Animal experiments have been approved by the Institutional Animal Ethics Committee for Ain Shams University, Faculty of Medicine (No. FWA 00021368, 5/2021). Thirty
Wistar male rats (weight 150–200 g) have been acquired from the National Research Institute (Cairo, Egypt). The animals were housed with lighting control (12 h light/dark cycle)
at 22 ◦ C. An adaptation period of 1 week was allowed before admission of the experimental
procedure. The rats have been randomly and equally divided into 5 groups (n = 6):
Group I; The control group.
Group II; Chronic alcohol ingestion (10 g/kg/day) [30].
Group III; Atorvastatin (10 mg/kg/day, p.o.) treated [31].
Group IV; Chronic alcohol ingestion + atorvastatin.
Group V; Chronic alcohol ingestion + atorvastatin + ASA (10 mg/kg/day, p.o.) [32].
2.2. Chemical Reagents and Drugs
Absolute ethanol (100%), atorvastatin and ASA have been acquired from the Sigma
Chemical Company, Cairo, Egypt [30,33,34].
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2.3. Induction of Alcoholic Brain Injury
After acclimation for 6-7 days, the animals were treated with alcohol (10 g/kg; oral
gavage) as a water solution (with solutions maximally containing 56% alcohol) for 10 weeks
and treated with atorvastatin (10 mg/kg) alone and/or in combination with a dose of ASA
(10 mg/kg) for the same duration. All rats had frequent standard rat chow available during
the 6-week period [28].
2.4. Cognitive Function Assessment; Morris Water Maze (MWM)
The Morris water maze (diameter 1.8 m) was used for testing, along with a "Atlantis
platform" (diameter 10 cm). The platform was placed in the middle of the pool's northeast
quadrant, the water was made dim with powdered milk, and the chamber was lighted by
four 30-W spotlights pointing at the ceiling. The water was kept at a constant temperature
of 23 ◦ C. Numerous constants, or prominent visual signals, were present in the testing room
(posters, objects, and equipment). A video camera was installed just above the pool on the
ceiling to monitor each rat's swim path. Each day for five days, rats underwent four trials
in the Morris water-maze, without any signals indicating the position of the platform. The
submerged platform remained constant in one quadrant of the maze throughout testing,
and the latency to locate it (as well as the distance travelled by the rats) were recorded.
Each trial in this and subsequent studies began with the precise placement of an individual
rat into the water, facing the pools outside edge, at one of four possible beginning places
(e.g., north, south, east, west). Each experiment began at a random site, with the proviso
that all start locations were used on any given day. A trial was ended, and the latency
was measured when the rat reached and remained on the platform for ten seconds. The
experiment was cancelled if the rat did not reach the platform within 120 seconds, and the
rat was placed on the platform for 10 seconds. Following that, rats were transported to a
dry holding cage for 60 seconds until the following session. Rats were moved to their home
cages following training. On the sixth day, rats received an additional 60-second probe
session in which the pool lacked a platform. As before, rats were placed in the pool and the
latency to reach the target quadrant as well as the duration spent within the quadrant of
the platform were recorded [35].
2.5. Biochemical Analysis
Stored brain samples (from frontal lobes) at −80 ◦ C were used in the determination of
the miRNA155, NLRP3 and IL-1β expression level.
Real-Time PCR
Total RNA was extracted utilizing a RNeasy Mini Kit. The RNA was reversed transcribed utilizing a QuantiTect Reverse Transcription Kit and real-time PCR was performed
for the miRNA155 NLRP3 and IL-1β using a QuantiTect SYBR Green PCR Kit. The kits
were acquired from Qiagen, Hilden, Germany. β-actin has been utilized as the housekeeping
gene. The miRNA155 primers were Forward: 50 -AGGGAAATCGTGCGTGAC-30 , Reverse:
50 -CGCTCATTGCCGATAGTG-30 (GenBank NM_031144.3). For the NLRP3, the primers were
Forward: 50 −CCAGGGCTCTGTTCATTG-30 , Reverse: 5-CCTTGGCTTTCACTTCG-30 (GenBank NM_001191642.1) and for the IL1β, the primers were Forward: 50 -CACCTTCTTTTCCTT
CATCTTTG-30 , Reverse: 50 -GTCGTTGCTTGTCTCTCCTTGTA-30 (GenBank NM_031512.2).
The PCR reaction mixture was 20 µL and contained 500 ng RT product and 0.5 µM of each
primer. The cycling technique included initial heating for 15 min at 95 ◦ C followed by
40 cycles. Each cycle consisted of a denaturation stage for 15 s at 94 ◦ C, annealing step for
30 s at 55 ◦ C, and extension step for 30 s at 70 ◦ C. The relative expression of target genes
was estimated using the 2−∆∆Ct equation.
2.6. Histology Study
The frontal lobe of the brain was extracted immediately at the end of the experiment
and divided into two halves for the following analysis:
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i.

Light microscopic (LM) analysis

Half of the frontal lobe was divided into small pieces and immersed in 10% of neutral
buffered formalin followed by dehydration to get paraffin blocks for the LM analysis.
The paraffin blocks have been divided into sections with 5 micron-thick for a H&E stain.
Immunohistochemical staining has been performed employing an avidin biotin-peroxidase
method for the detection of cleaved caspase-8 (acquired from Cell Signaling Technology,
Danvers, MA, USA). The reaction was performed with a DAB solution (acquired from
DAKO, Glostrup, Denmark) for 10 min. Subsequently, the counterstain was performed
utilizing Mayer’s hematoxylin. The sections for negative control were obtained following
the same protocol, with the exception of the use of the primary antibody [36].
ii.

Semi-thin sections analysis

Examining semi-thin sections—stained with toluidine blue—was a very important step
before preparing ultrathin sections to be examined by a transmission electron microscope
(TEM). The semi-thin sections helped in examining a large field of the specimen with a
good resolution using a light microscope. This was important to locate and trim the specific
area in the specimen that was required to be later examined by the TEM. This is especially
relevant in brain samples where it is very important to determine the brain region that
will be studied. In addition, the high resolution of the brain semi-thin sections helped in
differentiating between the neurons and glial cells by their morphology and the specific
criteria of their nuclei. This was based on an algorithm that can be used to systematically
distinguish the cellular types in the cerebral cortex, using semi-thin and ultrathin brain
sections [37].
iii.

Transmission electron microscopic (TEM) analysis

The half of the frontal lobe material was chopped into small (1 mm3 ) pieces and
preserved in 2.5% glutaraldehyde for TEM analysis. Subsequently, we cut semi-thin
sections (1 µm) and stained them with toluidine blue stain. Ultra-sections as thin as 80 nm
were stained with lead citrate and uranyl acetate before being analyzed by TEM (Joel,
Tokyo, Japan) at the EM unit, Ain Shams University, Faculty of Science [38].
2.7. Morphometric Study
The image analyzer computer system, Leica Qwin 500, UK at the Faculty of Medicine,
Ain Shams University, Department of Histology and Cell Biology, was used to evaluate
the cerebral cortex thickness (frontal cortex) (×20 power lens) and the area % of Caspase-8
positive reaction in the cells of the cerebral cortex (×40 power lens). Each parameter was
assessed in 5 fields of two serial sections in each group for all animals.
2.8. In Silico Molecular Modelling Study
The binding affinity of ASA was explored toward the active site of the NLRP3 protein
by in silico molecular docking using Molecular Operating Environment software (MOE® ,
2015.10). In the protein data bank (PDB), there was only two crystal structures available for
the NLRP3 domain in complex with a substrate and/or 2-furanylsulfonyl-urea derivative
inhibitor (PDB code: 7alv and 6npy) [39,40]. To deeply investigate the potency of ASA as
an inhibitor for the NLRP3 protein, we have explored their binding toward the different
available 3D crystal structures of the NLRP3 protein. The 3D structures of the NLRP3 (PDB
code: 7alv and 6npy) were retrieved from PDB (http://www.rcsb.org/pdb, 6 February
2022). The structures of the ASA were obtained in 2D using the ChemDraw program. The
3D structures of the ASA were obtained as MDB files employing the Discovery Studio
software. The extra chains and water molecules were deleted. The 3D protonated protein
structure was obtained employing the default protocol in the MOE program. Energy
minimization, expression of partial charges, and geometry optimizations were obtained by
applying the default Conf Search module and MMFF94x force field in the MOE program.
The docking protocol was applied using the London dG scoring function and Triangle
Matcher placement method as reported previously [41–46]. The docking parameters and
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protocol were then validated by redocking the co-crystallized ligand into the active site of
the protein. The obtained binding poses were then compared to that of the reported crystal
structure to affirm the similarity in binding mode. The validated protocol was then used
to dock the ASA to the NLRP3 binding site to explore their binding affinity. The acquired
results were collected and assessed to obtain the poses with the highest protein-ligand
binding scores.
2.9. Statistical Analysis
Sample size was defined utilizing the GraphPad StatMate software program, 16 January
1998 Version 1. Statistical analysis was employed utilizing the GraphPad Prism software
program, version 5.0 (2007) (Inc., San Diego, CA, USA) and Excel (2007). Statistical difference among the groups has been defined employing one-way (ANOVA) analysis, followed
by a post hoc Tukey test to compare between more than two groups.
3. Results
3.1. Effect of Alcohol and/or ATOR Treatment on Cognitive Function and Assessment of ASA
Administration
We first examined the effect of alcohol administration and ATOR intake on cognitive
function by using the Morris water maze test. As shown in Table 1, the administration
of alcohol and/or ATOR induced a significant increase in latency time to reach the target
quadrant in 1–6 days, while a significant decrease was observed in the percentage of time
spent in the target quadrant during the sixth day. These results could be attributed to the
direct toxic effect of alcohol on the brain and through the release of various mediators such
as an inflammatory, endogenous antioxidant, caspases and brain-derived neurotrophic
factor BDNF, which mainly affects the prefrontal area. The ATOR treatment can also
potentiate the neuroinflammatory process via the activation of NLRP3 and its subsequent
mediator IL1B-inducing cognitive impairment. Interestingly, the ASA treatment decreased
the latency time to reach the target quadrant in the six days and significantly decreased the
percentage time spent in the target quadrant on the sixth day (p < 0.001), when compared
to the alcohol and/or ATOR groups. These results indicate that ASA with its nonsteroidal
anti-inflammatory effect could repress the production of pro-inflammatory molecules
and accordingly decrease the neuro-inflammation and oxidative stress in the CNS. This
pleiotropic mode of action of the ASA could aid in the prevention of cognitive decline in
rats treated with alcohol and/or ATOR.
Table 1. Assessment of cognitive function in the different treated groups by the Morris water maze
(MWM) test (mean ± SD).
Groups Latency to Reach
Target Quadrant (s)

Day 1

Control group

6.68 ± 19.9

27.88 ± 6.6

Alcohol group

10.9 ± 9.9 a

67.63 ± 5.4 a

ATOR group

8.06 ± 17.2 a

50.77 ± 10.2 a

80.9 ± 9.8 a

Alcohol + ATOR group
Alcohol + ATOR + ASA group

Day 2

a

13.71 ± 7.3
7.73 ± 16.6 abcd

Day 3

a

85.19 ± 8.8
33.1 ± 15.1 abcd

% Time Spent in
Target Quadrant

Day 4

Day 5

22.18 ± 8.1

15.3 ± 7.5

8.37 ± 2.5

7.7 ± 4.9

47.33 ± 7.5

92.9 ± 7.1 a

55.52 ± 6.3 a

45.38 ± 8.2 a

21.08 ± 7.2 a

19.25 ± 5.9 a

35.33 ± 13.3 a

19.17 ± 6.4 a

21.6 ± 10.3 a

32.6 ± 5.8 a
a

71.46 ± 7.7
32.23 ± 7.1 abcd

a

48.23 ± 13.2
21.17 ± 11.4 abcd

Day 6

a

55.5 ± 11.9
21.9 ± 11.0 abcd

a

33.17 ± 9.2
15.08 ± 5.2 abcd

12.81 ± 14.9 a
36.6 ± 18.2 bcd

Data are mean ± SD of 6 rats per group. p < 0.05 is significant; a P versus control group, b P versus Alcohol group,
c P versus ATOR group, d p versus Alcohol + ATOR + ASA group.

3.2. Biochemical Analysis
3.2.1. Effect of Alcohol and/or ATOR Treatment on miRNA155 Expression and Influence of
ASA Administration
Dysregulation of brain miRNAs has been recently correlated to alcohol exposure.
The upregulation of miRNA155 expression in brain tissue was found to induce neuroinflammation via amplification of IL-1β, IL-6 and TNF-α with an implication on cognitive
dysfunction; however, the correlation between miRNA155 and alcohol-induced cognitive
impairment associated with an ATOR treatment is still elusive. To gain insights into this
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Effect
of ASA
on Brain
NLRP3 andgroup
IL-1β Expression
after Alcohol
and/or
the other
hand,
the ASA-treated
showed a significant
decrease
(p ATOR
< 0.0001)
Treatment
in brain miRNA155 expression, indicating the ability of ASA to reduce the possible neuroinflammation
induced by miRNA155
overexpression
that occurred of
due
to the alcohol and/or
Neuroinflammation
is a known
factor in the pathogenesis
neurodegenerative
disATOR
administration.
These
results
could
be
attributed
to
the
ASA’s
anti-inflammatory
eases and impairs the cognition and memory function. To examine the process of neuroinproperties
andthe
itsexpression
ability to downregulate
TNF-α-and
NF-κB-dependent
miR-155intranscripflammation,
of NLRP3 and
IL-1β were
examined. As depicted
Figure 2,
tional biogenesis.
3.2.2. Effect of ASA on Brain NLRP3 and IL-1β Expression after Alcohol and/or ATOR
Treatment
Neuroinflammation is a known factor in the pathogenesis of neurodegenerative diseases and impairs the cognition and memory function. To examine the process of neuroinflammation, the expression of NLRP3 and IL-1β were examined. As depicted in Figure 2,
the administration of alcohol and/or ATOR significantly increased (p < 0.0001) NLRP3
and IL1 β expression. These results reveal the possible role of NLRP3 inflammasome in
promoting neuroinflammation and aggravating cognitive impairment upon alcohol and/or
ATOR intake. NLRP3 inflammasome has been known as a key contributor to promote the
secretion of pro-inflammatory IL-1β and the formation of caspase-1, which leads to aggravating the inflammatory reaction, neutrophil infiltration, neurotoxicity and a worsening
neurological function.
The ASA treatment caused a significant decrease (p < 0.0001) in the NLRP3 and IL1β brain expression and was able to ameliorate the process of neuroinflammation and
consequently the cognitive impairment induced by the administration of alcohol and/or
ATOR. This could be explained by the ability of the ASA to downregulate pro-IL-1β and proIL-18 transcription and to stimulate the brain autophagy leading to elimination of impaired
brain mitochondria and reactive oxygen species, which finally leads to the amelioration
of neuroinflammation and cognitive decline. Overall, ASA could induce high epigenetic
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The ASA treatment caused a significant decrease (p < 0.0001) in the NLRP3 and IL-1β
brain expression and was able to ameliorate the process of neuroinflammation and consequently the cognitive impairment induced by the administration of alcohol and/or ATOR.
This could be explained by the ability of the ASA to downregulate pro-IL-1β and pro-IL8 of 26
18 transcription and to stimulate the brain autophagy leading to elimination of impaired
brain mitochondria and reactive oxygen species, which finally leads to the amelioration
of neuroinflammation and cognitive decline. Overall, ASA could induce high epigenetic
regulation
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IL1ββexpression
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braintissue
tissue(Figure
(Figure2).
2).
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3.3.Histological
HistologicalResults
Results
3.3.
3.3.1. Light Microscopic Analysis
3.3.1. Light Microscopic Analysis
To affirm our biochemical results, the effect of chronic alcohol and/or ATOR intake
To affirm our biochemical results, the effect of chronic alcohol and/or ATOR intake
on brain tissue and the possible protective effect of ASA was implemented using light
on brain tissue and the possible protective effect of ASA was implemented using light
microscopic examination of H&E stained brain sections. Light microscopic examination of
microscopic examination of H&E stained brain sections. Light microscopic examination
the control group (Group I) showed that the frontal cortex was formed of six layers with no
of the control group (Group I) showed that the frontal cortex was formed of six layers with
sharp demarcations; molecular, outer granular, outer pyramidal, inner granular, inner pyrano sharp demarcations; molecular, outer granular, outer pyramidal, inner granular, inner
midal and multiform (Figure 3A). These layers contained nerve cells (mainly pyramidal
pyramidal and multiform (Figure 3A). These layers contained nerve cells (mainly pyramcells and granule cells) and glial cells. Nerve cells (pyramidal (P) and granule (G)) in the
idal cells and granule cells) and glial cells. Nerve cells (pyramidal (P) and granule (G)) in
different layers of the cerebral cortex appeared as large cells with large, rounded nuclei and
the different layers of the cerebral cortex appeared as large cells with large, rounded nuclei
prominent nucleoli. The nerve cells were separated by homogenous neuropil, containing
and
prominent
nucleoli.
The nerve cells
were glial
separated
by homogenous
consmall,
deeply stained
nuclei—most
probably
cells—(Figure
3B). The neuropil,
alcohol-treated
taining
small,
deeply
stained
nuclei—most
probably
glial
cells—(Figure
3B).
The
alcoholgroup (Group II) showed distortion of the layers of the cerebral cortex. Occasionally, areas
of aggregated mononuclear inflammatory cells (granuloma) were seen (Figure 3C). Most of
the pyramidal cells and granule cells in the different layers were shrunken, condensed, and
deeply stained and surrounded by a hallow. Small, deeply stained nuclei—most probably
glial cells—were also surrounded by hallows. The neuropil was pale and vacuolated,
and the blood vessels were dilated (Figure 3D). In the ATOR-treated group (Group III),
some pyramidal cells and granule cells were shrunken, condensed, deeply stained and surrounded by hallows; however, some nerve cells had large, rounded nuclei and prominent
nucleoli. Small, deeply stained nuclei, most probably glial cells, were also surrounded by
hallows. The neuropil was pale and vacuolated. Some dilated blood vessels were seen
(Figure 3E). The alcohol-group treated with ATOR (Group IV) showed distorted layers of
the cerebral cortex. Many pyramidal cells and granule cells were shrunken, condensed,
deeply stained and surrounded by hallows. Few nerve cells had large, rounded nuclei and
prominent nucleoli. Small, deeply stained nuclei—most probably glial cells—were also
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treated group (Group II) showed distortion of the layers of the cerebral cortex. Occasionally, areas of aggregated mononuclear inflammatory cells (granuloma) were seen (Figure
3C). Most of the pyramidal cells and granule cells in the different layers were shrunken,
surroundedand
by hallows.
The neuropil
was pale and
Dilated
blood
condensed,
deeply stained
and surrounded
by markedly
a hallow. vacuolated.
Small, deeply
stained
nuvessels were
seen (Figure
3F). Finally, also
the alcohol-group
with
the ATOR
and
clei—most
probably
glial cells—were
surrounded bytreated
hallows.
Theboth
neuropil
was pale
ASA
(Group V) showed
more
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arrangement
of the
layers of
theIn
cerebral
cortex. Most
and vacuolated,
and the
blood
vessels
were dilated
(Figure
3D).
the ATOR-treated
of the pyramidal
and
granule
cells had
large,
Someshrunken,
nuclei hadcondensed,
prominent
group
(Group III),
some
pyramidal
cells
androunded
granulenuclei.
cells were
nucleoli
and
others
were
vacuolated.
Some
small,
deeply
stained
nuclei,
most
deeply stained and surrounded by hallows; however, some nerve cells had large, probably
rounded
glial cells,
surrounded
by Small,
hallows.
The neuropil
appeared
homogenous
andcells,
few
nuclei
and were
prominent
nucleoli.
deeply
stained nuclei,
most
probably glial
dilated
blood
vessels were
detectedThe
(Figure
3G). was pale and vacuolated. Some dilated
were
also
surrounded
by hallows.
neuropil
we have
of the treated
frontal cortex.
A morphometric
bloodMoreover,
vessels were
seen investigated
(Figure 3E). the
Thethickness
alcohol-group
with ATOR
(Group IV)
study showed
a significant
decrease
in cortex.
the mean
thickness
of the
frontal
the
showed
distorted
layers of the
cerebral
Many
pyramidal
cells
and cortex
granuleincells
alcohol-group
(Group
II)
as
compared
to
the
control
group
(Group
I),
ATOR-treated
group
were shrunken, condensed, deeply stained and surrounded by hallows. Few nerve cells
(Group
III)rounded
and alcohol-group
withnucleoli.
ATOR +Small,
ASA deeply
(Group stained
V). While
it showed
had
large,
nuclei and treated
prominent
nuclei—most
non-significant
change
as
compared
to
the
alcohol-group
treated
with
ATOR
(Group
IV).
probably glial cells—were also surrounded by hallows. The neuropil was pale and markOn
the
other
hand,
Group
V
showed
a
significant
increase
as
compared
to
Group
II,
Group
edly vacuolated. Dilated blood vessels were seen (Figure 3F). Finally, the alcohol-group
III and Group
IV. Moreover,
non-significant
change
when
compared
to Group
treated
with both
the ATORthere
and was
ASAa(Group
V) showed
more
regular
arrangement
of
V
to
Group
I,
as
well
as
for
Group
II,
Group
III
and
Group
IV
when
compared
to
each
the layers of the cerebral cortex. Most of the pyramidal and granule cells had large,
other (Table
2). These
that therenucleoli
was damage
that occurred
in the prefrontal
rounded
nuclei.
Someresults
nucleiindicate
had prominent
and others
were vacuolated.
Some
cortex
due
to
chronic
alcohol
intake
associated
with
the
ATOR
administration.
WhileThe
the
small, deeply stained nuclei, most probably glial cells, were surrounded by hallows.
treatment
with
the
ASA
improved
these
damages.
neuropil appeared homogenous and few dilated blood vessels were detected (Figure 3G).
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3. Photomicrograph
Photomicrograph of brain tissue
sixsix
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of
Figure
tissue (H&
(H&EEstain)
stain)from
from(A,B)
(A,B)Group
GroupI,I,showing
showingthe
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layers
thethe
cerebral
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inin
the
(P) and
and granule
granule
of
cerebral
cortex
thecontrol
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group(H&E
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100). The
The nerve cells (pyramidal (P)
(G))
(G)) in
in the
thedifferent
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ofthe
thecerebral
cerebralcortex
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withlarge,
large,rounded
roundednuclei
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prominentnucleoli.
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Nerve
Nerve cells
cells are
are separated
separated by
by homogenous
homogenous neuropil,
neuropil, containing
containing small,
small, deeply
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stained nuclei—most
nuclei—most
probably
glial
cells—(↑)
(H&E
×
400).
(C,D)
Group
II
showed
distorted
layers
of
probably glial cells—(↑) (H&E × 400). (C,D) Group II showed distorted layers ofthe
thecerebral
cerebralcortex
cortex
in the alcoholic group. An area of aggregated mononuclear inflammatory cells (granuloma) can be
in the alcoholic group. An area of aggregated mononuclear inflammatory cells (granuloma) can be
seen (▲) (H&E × 100). Most of the pyramidal cells (P) and granule cells (G) in the different layers
seen (N) (H&E × 100). Most of the pyramidal cells (P) and granule cells (G) in the different layers
seen are shrunken, condensed, deeply stained and surrounded by a hallow. Small, deeply stained
seen are shrunken,
condensed,
deeplyalso
stained
and surrounded
by (↑).
a hallow.
deeply
stained
nuclei—most
probably
glial cells—are
surrounded
by hallows
NoticeSmall,
the pale,
vacuolated
nuclei—most
probably
glial
cells—are
also
surrounded
by
hallows
(
↑
).
Notice
the
pale,
vacuolated
neuropil (*) and the dilated blood vessel (V) (H&E × 400). (E) Group III, some pyramidal cells (P)
neuropil
(*) and
blood
vessel (V)
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stained
surrounded
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surrounded
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Notice
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rounded
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prominent
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(▲). Small,
deeply
stained
nuclei—most
probably
glial
cells—are
also
surrounded
by
hallows
(↑).
The
neuropil
is pale
Notice some nerve cells have large, rounded nuclei and prominent nucleoli (N). Small, deeply stained
and
vacuolated
(*).
A
dilated
blood
vessel
(V)
is
seen
(H&E
×
400).
(F)
Group
IV
showed
distorted
nuclei—most probably glial cells—are also surrounded by hallows (↑). The neuropil is pale and
layers
of the(*).
cerebral
cortex
in vessel
group (V)
IV. isMany
pyramidal
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and IV
granule
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(G) arelayers
seen
vacuolated
A dilated
blood
seen (H&E
× 400).
(F)(P)
Group
showed
distorted
shrunken, condensed, deeply stained and surrounded by hallows. Notice few nerve cells have large,
of the cerebral cortex in group IV. Many pyramidal cells (P) and granule cells (G) are seen shrunken,
rounded nuclei and prominent nucleoli (▲). Small, deeply stained nuclei—most probably glial
condensed, deeply stained and surrounded by hallows. Notice few nerve cells have large, rounded
cells—are also surrounded by hallows (↑). Dilated blood vessels (V) are seen (H&E × 400). (G) Group
nuclei
andaprominent
nucleoli
(N). Small,
stained
nuclei—most
cells—are
V
showed
more regular
arrangement
of deeply
layers of
the cerebral
cortex probably
in group glial
V. Most
of the also
pysurrounded
by
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(
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).
Dilated
blood
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(V)
are
seen
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×
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(G)
Group
V
ramidal(P) and granule (G) cells have large, rounded nuclei. Some nuclei have prominentshowed
nucleolia
moreothers
regular
of layers
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group V. Mostprobably
of the pyramidal(P)
and
and
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vacuolated (∆).
Someofsmall,
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stained
glial cells—are
granule (G) by
cells
have large,
rounded
surrounded
hallows
(↑) (H&E
× 400).nuclei. Some nuclei have prominent nucleoli and others are
vacuolated (∆). Some small, deeply stained nuclei—most probably glial cells—are surrounded by
Moreover,
have investigated the thickness of the frontal cortex. A morphometric
hallows
(↑) (H&Ewe
× 400).

study showed a significant decrease in the mean thickness of the frontal cortex in the alcohol-group (Group II) as compared to the control group (Group I), ATOR-treated group
(Group III) and alcohol-group treated with ATOR + ASA (Group V). While it showed nonsignificant change as compared to the alcohol-group treated with ATOR (Group IV). On
the other hand, Group V showed a significant increase as compared to Group II, Group
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Table 2. Effect of alcohol and/or ATOR on mean thickness of frontal cortex and assessment of ASA
treatment (mean ± SD).
Group

Mean Thickness of Frontal Cortex

Group I

1832.15 ± 198.5

Group II

1455.60 ± 78.3 a

Group III

1644.70 ± 185.2 b

Group IV

1554.16 ± 69.8 c

Group V

1800.70 ± 167.3 d

a

Significant decrease compared to groups I, III and V, non-significant change compared to IV. b Significant
change compared to groups, I, II and V, non-significant change compared to IV. c Significant change compared to
groups I and V, non-significant change compared to II, III. d Significant increase compared to groups II, III and IV,
non-significant change compared to I.

3.3.2. Caspase-8 Immunostained Analysis
Caspase-8 is considered as a pro-apoptotic initiator which mediates the production
of IL-1β and hence neuroinflammation. In order to investigate the role of caspase-8 in
the process of neuroinflammation under treatment with alcohol and/or ATOR, and the
possible protective role of ASA, caspase-8 immunostained analysis on the brain tissue was
performed. A negative caspase-8 immune-reaction was detected in the nerve cells and
glial cells in the frontal cortex of the control group (Figure 4A). The alcohol-treated group
(Group II) showed a positive immune-reaction to caspase-8 (seen as a dark brown reaction)
in the cytoplasm of many nerve cells and glial cells (Figure 4B). The ATOR-treated group
(Group III) and the alcoholic group treated with ATOR (Group IV) showed a significant
decrease in the percentage area of caspase-8 expression in the nerve cells and glial cells
compared to the alcoholic group (Group II). While they showed a significant increase as
compared to the control group (Group I) and the alcoholic group treated with ATOR and
ASA (Group V), they did, however, show a non-significant change when compared to each
other (Figure 4C,D, respectively). In contrast, the alcoholic group treated with the ATOR
and ASA (Group V) showed a minimal or negative (in some fields) immune-reaction to
caspase-8 in both the nerve cells and glial cells. Indeed, Group V statistically showed a
non-significant change compared to the control group, but it showed a significant decrease
when compared to all other groups (Figure 4E) (Table 3). These results indicate that the
treatment with alcohol and/or ATOR significantly increased the expression of caspase-8,
and that the ASA treatment was able to diminish caspase-8 expression in the nerve cells
and glial cells of the frontal cortex.
Table 3. Effect of alcohol and/or ATOR treatment on caspase-8 immune reaction and the influence of
ASA administration (mean ± SD).

a

Group

Area % of Caspase-8 Positive Immune Reaction

Group I

0

Group II

4.41 ± 0.5 a

Group III

1.75 ± 0.3 b

Group IV

2.73 ± 0.4 c

Group V

0.42 ± 0.1 d

Significant increase compared to all groups. b Significant change compared to groups I, II and V and nonsignificant change compared to IV. c Significant change compared to groups I, II and V and non-significant change
compared to III. d Significant decrease compared to groups II, III and IV and non-significant change compared to I.
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and non-significant change compared to III. d Significant decrease compared to groups II, III and
IV and non-significant change compared to I.
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Figure 4.
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cytoplasm of some nerve cells and glial cells. (E) Group V showed a negative caspase-8 immunecytoplasm of some nerve cells and glial cells. (E) Group V showed a negative caspase-8 immunereactions in nerve cells and glial cells in the frontal cortex of group V. (Avidin Biotin Peroxidase for
reactions in
nerve cells and glial cells in the frontal cortex of group V. (Avidin Biotin Peroxidase for
Caspase-8
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Caspase-8 × 400).

3.3.3. Semi-Thin Sections Analysis
3.3.3. Semi-Thin Sections Analysis
Next, we performed semi-thin sections analysis on the brain tissue in order to explore
Next, we performed semi-thin sections analysis on the brain tissue in order to explore
the effect of chronic alcohol treatment and/or ATOR intake and the possible protective
the effect of chronic alcohol treatment and/or ATOR intake and the possible protective
effect of ASA on the cells which are involved in the process of cognitive impairment and
effect of ASA on the cells which are involved in the process of cognitive impairment
neuroinflammation. Examination of the semi-thin sections of the frontal cortex for the
and neuroinflammation. Examination of the semi-thin sections of the frontal cortex for
the control group (Group I) showed pyramidal cells with large rounded vesicular nuclei
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control group (Group I) showed pyramidal cells with large rounded vesicular nuclei
and
prominent nucleoli. Nissl granules were seen in their cytoplasm. Granule cells were seen
with small rounded euchromatic nuclei surrounded by a rim of cytoplasm. Different types
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Nissl
granules
were seen
in their
cells
ofand
glial
cells were
seen with
their
characteristic
features:
thecytoplasm.
astrocytes Granule
had large,
pale
were
seen
with
small
rounded
euchromatic
nuclei
surrounded
by
a
rim
of
cytoplasm.
nuclei with a dense rim of peripheral heterochromatin; the oligodendrocytes had rounded
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3.3.4. Transmission Electron Microscopic (TEM) Study
To gain deep insight into our previous histological results and to explore the possible
protective effect of ASA on brain tissue upon chronic alcohol abuse and/or ATOR treatment, extensive transmission electron microscopic examinations of ultra-thin sections of
the frontal cortex were performed. TEM analysis for the control group showed pyramidal
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nucleus (Nu) is seen surrounded by cytoplasm. Notice the rough endoplasmic reticulum (rER) and
mitochondria (m). Inset showing an astrocyte (A) Inset (TEM × 2000). (B) Group I, demonstrating
a nerve cell with dilated, irregularly arranged cisternae of rough endoplasmic reticulum (rER).
Notice the presence of lysosomes (Ly), vacuoles (↑) and a Golgi apparatus (GA) in the nerve cell.
Notice the presence of an astrocyte (A) with irregular dark nucleus. Large vacuoles (*) are seen
in the neuropil (TEM × 1500). (C) Group II, showing a nerve cell in the frontal cortex of Group II
with large, rounded, central and euchromatic nucleus (Nu). Notice the intranuclear vacuoles (↑).
Lysosomes (Ly), elongated mitochondria (m) and cytoplasmic vacuoles are seen. Notice a microglial
cell is present beside the nerve cell. Many large vacuoles are seen in the neuropil (*) (TEM × 1500).
(D) Group II, showing two glial cells in the frontal cortex of Group II. An astrocyte (A) is seen with
an irregular dark nucleus and a dense rim of peripheral heterochromatin. Notice the dilated and
distorted cisternae of rough endoplasmic reticulum (rER), mitochondria (m) with destroyed cristae
and cytoplasmic vacuoles (↑). An oligodendrocyte (O) is seen with its dark oval nucleus and large
clumps of heterochromatin. Multiple dense bodies are seen in its cytoplasm (N). Large vacuoles are
seen in the neuropil (*) (TEM × 2500). (E) Group III, showing pyramidal cells in the frontal cortex of
Group III with large, rounded, central and euchromatic nuclei (Nu). Notice mild dilatation of the
rough endoplasmic reticulum (rER). Lysosomes are seen (Ly). An oligodendrocyte (O) is present
beside a nerve cell. Inset: showing a pyramidal cell with darkly stained irregular nucleus (TEM ×
1200). (F) Group IV, showing a pyramidal cell in frontal cortex with marked deep indentation of the
nuclear membrane (Nu1). Many lysosomes are seen (Ly). An astrocyte (A) is present beside the nerve
cells. Inset: showing a pyramidal cell with indented and irregular nucleus (Nu2). Large vacuoles are
seen in the neuropil (*) (TEM × 1200). (G) Group V, showing pyramidal cells in the frontal cortex
of Group V with large, rounded, central and euchromatic nuclei (Nu). Notice mild dilatation of a
few rough endoplasmic reticulum cisternae (rER). Few lysosomes are seen (Ly). An astrocyte (A)
is present beside a nerve cell. The neuropil is homogenous (*). Inset: showing a microglial cell (M)
(TEM × 1200).

3.4. In Silico Molecular Docking Study
In silico molecular modelling represents a modern computational analysis that can
be applied in investigating the possible mode of action for a drug [47]. To further explore
the possibility of ASA to target the NLRP3 protein, we performed an extensive in silico
molecular docking study to investigate the binding affinity of ASA into the active sites of
the binding pockets of the NLRP3 protein. In the protein data bank, there were only two
PDB codes available for NLRP3 proteins (PDB codes, n6py and 7alv) which represent the 3D
structure of theNLRP3 NACHT domain co-crystallized with a potent inhibitor (NP3-146)
and/or ADP [39,40]. To gain insights into the different possible modes of binding for ASA,
we performed molecular docking studies for both 3D crystal structures available (PDB
codes, n6py and 7alv), and the obtained results were isolated to be evaluated (Table 4).
The obtained poses were evaluated and selected based upon the capability of the docked
ligand to possess the main binding interactions to the active site of the binding protein.
After adjusting different parameters, we examined our docking protocol by redocking the
co-crystallized ligand, either ADP or NP3-146, to the active sites of the NLRP3 NACHT
domain to ensure that the re-docked ligand could form the main interactions reported in
the database. Next, the validated docking protocol was used to investigate and to assess
the binding affinity of ASA to the ADP-binding site and the inhibitory-binding site of the
NLRP3 NACHT domain. The obtained results from the docking study, docking score and
observed binding interactions, are presented in Table 4. Based on the recently reported
crystal structure, the NLRP3 NACHT domain had two binding sites: an ADP-binding site
and inhibitory-binding site [39,40]. Our results revealed that the ASA had high binding
scores to both ADP- and inhibitor-binding pockets with the ability to bind to the active
sites of the NLRP3 NACHT domain by both hydrophilic and hydrophobic interactions in a
similar mode compared to the original co-crystallized ligands (Figure 7, Table 4). These
results indicate that the suppression effect of ASA on cognitive dysfunction could be also
attributed to its ability to target the NLRP3 protein.
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Alcohol abuse induces brain neurodegeneration resulting in elevation of proinflammatory cytokines and chemokines expression and, in particular, microglia can be
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in left and right precentral gyri, as well as in subcortical regions like the left thalamus and
right hippocampus [51].
Alcohol abuse induces brain neurodegeneration resulting in elevation of proinflammatory cytokines and chemokines expression and, in particular, microglia can be activated
through their receptors (such as Toll-like receptor 4) [52]. Robust changes in miRNA expression have been reported in the prefrontal cortex of subjects with a history of chronic
alcohol abuse [17], which may provide the opportunity to evaluate ongoing changes in
the CNS upon the initiation of neurodegeneration [53]. Among the different miRNA,
miRNA155 is highly expressed in numerous tissues, including the brain, suggesting its proinflammatory action in CNS. miRNA155 induces neuroinflammation through a reduction
in the endogenous anti-inflammatory response resulting in increased inflammation [54].
Neuroinflammation has been identified as a causative factor of multiple neurodegenerative diseases. The NLRP3 inflammasome—a subcellular multiprotein complex that is
abundantly expressed in the CNS—can be activated by a wide range of exogenous and
endogenous stimuli [55]. Activation of the NLRP3 inflammasomes pathway is responsible
for neuroinflammation and is associated with several brain diseases [56]. Toll-like receptors
(TLRs) in the CNS trigger the activation of pro-IL-1β and pro-IL-18 that are converted into
their active forms by the NLRP3 inflammasome [57].
Alcoholic fatty liver (steatosis), alcoholic hepatitis, and fibrosis are associated with
the progression of liver cirrhosis, with the highest risk in alcoholism [5]. Statins are lipidlowering drugs that are utilized to treat lipid disorders and commonly prescribed for
patients with fatty liver diseases to reduce low-density lipoprotein cholesterol [8]. The
exact effect of statins on cognitive function has been not fully addressed; however, it was
suggested that statins may cause a short-term cognitive impairment [58,59]. Cholesterol
is a crucial lipid for brain functions, and it is used in the formation of the nervous system as well as the manufacture of steroid hormones that are involved in brain signaling.
Accordingly, decreasing the serum cholesterol level, upon statins treatment, may affect
cognition function [25]. Interestingly, it was suggested that switching from lipophilic statins
(e.g., ATOR) to hydrophilic statins could resolve the cognitive impairment with vascular
benefits [60].
Based on the abovementioned facts, in the present study we aimed at investigating
the molecular and cellular effects of ATOR on cognitive dysfunction induced by alcohol
intake. Accordingly, rats were treated with alcohol and/or ATOR and a set of biochemical,
histopathological, and immunohistochemical analyses were performed. A Morris water
maze test showed that the cognitive function was significantly impaired, as indicated by
the increase in latency time to reach the target quadrant and the decrease in the % time
spent in the target quadrant. Our results were in accordance with the previous findings
which reported a significant impairment in the Morris water maze test for rats treated with
alcohol, together with an impairment in the memory as demonstrated by the markedly
increased latency time [61,62]. Further studies have showed that alcohol intake causes
various neurological diseases via the toxic effect of various key mediators on the brain,
such as inflammation, caspase-3, and the brain-derived neurotrophic factor BDNF [63].
Additionally, Stragier et al. reported that ethanol treatment in C57BL/6J mice causes
profound impairment in the learning and memory place [64]. Toward the effect of statins
on cognitive function, in accordance with our results, King et al. reported that statin therapy
significantly and temporally impairs cognitive function and recommended that clinicians
should be aware of cognitive impairment as a potential adverse effect associated with statin
therapy [65].
As the alcohol induced neuroinflammation in the brain, the IL-1β level increased
through the activation of the NLRP3 inflammasome [66]. Our results demonstrated a
pivotal role for NLRP3 inflammasome activation that mediates the IL-1β level in the
alcohol-related neuroinflammation. In agreement with Orio et al., we found that treatment
with alcohol or in combination with ATOR produced a significant increase in caspase-8 and
the IL1β and NLRP3 inflammasomes in the brain tissue [67]. Indeed, Orio et al. showed
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that alcohol abuse causes oxidative damage to the mitochondria and cellular proteins
which leads to the development of neuroinflammation and neurological disorders. Further,
the inflammasome components (NLRP1, NLRP3, ASC) and proinflammatory cytokines
(TNF-α) levels were increased in alcohol-treated brains, together with an enhancement of
caspase-1 activity and the IL-1β protein [21]. Our results revealed that the ATOR increased
the expression of IL-1β, caspase-8 and the NLRP3 inflammasome pathway. Statins possess
anti-inflammatory effects which lead to enhancing the activity of NLRP3 inflammasome
and IL-1β [68,69]. According to Peng et al. and Shu et al., ATOR has an antioxidant capacity
via increasing the level of GSSG/GSH, and is considered as an anti-inflammatory agent
and proinflammatory compound [70,71].
In the present study, the treatment with alcohol alone or in combination with ATOR
produced a significant increase in the expression of miRNA155 levels in the brain tissue.
Although previous studies have confirmed the relation between cognitive dysfunction
and miRAN155 expression, the link between miRNA155 expression and alcohol-induced
cognitive dysfunction was unique in our study. In our study, we hypothesized that the link
between alcohol-induced cognitive dysfunction and miRNA155 could be via the NLRP3
inflammasome pathway. This hypothesis was also supported by the recent findings by
Liu et al. which showed that miRNA155 expression increases in the hippocampus of AD
rats, together with IL-1β, IL-6 and TNF-α [18]. Our findings were in agreement with Yin
et al.’s study which showed that miRNA155 induced the expression of NLRP3 inflammasome which could induce the secretion of IL-1β and IL-18 leading to the development of
inflammation and atherosclerosis [72]. Silencing of miRNA155 was shown to significantly
decrease the inflammation and NLRP3/caspase-1 signaling [73].
As mentioned above, the brain tissue was affected by alcohol and/or ATOR administration leading to neuroinflammation. Our results were further confirmed by light
microscopic examination of the brain tissue. In the control group, the frontal cortex showed
a normal appearance with the six layers of the cortex formed of neurons and glial cells,
as previously described [74]. On the other hand, the groups treated with alcohol, ATOR
or a combination of both showed signs of degeneration in the neurons as well as the glial
cells, in the form of shrunken cells surrounded by hallows, a loss of Nissl’s granules (seen
in the semi-thin sections) and deeply stained, pyknotic nuclei. Interestingly, the alcoholic
group showed aggregations of inflammatory cells—most probably microglia—forming a
granuloma-like structure. These lesions were previously shown to be associated with the
degeneration of neurons that was caused due to the consumption of the alcohol and/or
ATOR [75]. Moreover, the present morphometric study showed a significant decrease in the
mean thickness of the frontal cortex in the alcoholic group as compared to the control group.
These results were in accordance with an Olawale et al. study which showed that cerebral
cortex damage, due to acute alcohol intake, is associated with oxidative stress [76]. Fortier
et al. reported that the thickness of the brain cortex significantly decreased in specific areas
in alcoholic compared with non-alcoholic members, suggesting that alcohol may affect the
large pyramidal cells in the frontal cortex [77]. Moreover, Saito et al. reported changes in
the count of glial cells after chronic ethanol exposure [52]. Together, these findings indicate
that alcohol consumption causes a decline in grey matter size in certain brain regions and
has effects on the behavioral depiction of these brain areas that may lead to cognitive
impairment [50].
Caspase-8 plays a central role in apoptosis, as well as regulating inflammation by
modulating IL-1β expression. In the present study, examination of caspase-8 stained
brain sections of the control group showed a negative reaction. While the alcoholic group
and ATOR-treated alcoholic group showed a positive reaction to caspase-8, in both the
nerve cells and the glial cells. Previous co-immunoprecipitation studies demonstrated
that caspase-8 presents in the NLRP3 inflammasome complex, where it is believed to be
involved in the cleavage of pro-caspase-1 [78]. Further, different inflammatory stimuli
can cause activation of NF-kB via the association of caspase-8 [79,80]. These results could
explain the observed increased caspase-8 in our investigations.
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pocket [39,40]. The ADP-binding pocket revealed a set of key amino acid residues (Thr231,
Ile232, Gly239, Thr167, Tyr166, His520, Lys 230) that interacted with one molecule of
ADP to form a stable network of hydrophilic interactions. While the recently discovered
inhibitor-binding pocket was shown to possess a slightly basic active site (Arg351, Arg578,
Pro352, Ala228) which mainly binds to the sulfonylurea part of the co-crystallized inhibitor
(NP3-146). As shown in Table 4, the ASA demonstrated high negatively-binding scores
toward the binding pockets of the NLRP3 NACHT domain, indicating that the binding of
ASA to the active sites of NLRP3 is thermodynamically favorable. Toward the ADP-binding
pocket, the ASA showed the ability to bind to the active site through interaction of the
carboxylic moiety to two of the main active amino acid residues (Ala228, Tyr632), and
an additional basic amino acid residue (Arg351). This interaction was also supported by
hydrophobic interactions with a set of greasy amino acid residues. Similarly, the ASA
showed the possibility to bind to the active site of the inhibitor-binding pocket via a
hydrophilic interaction with three of the main amino acid residues (Ala228, Arg351, Tyr632)
together with a set of hydrophobic interactions with greasy amino acid residues. Taken
together, our molecular docking study findings indicate that the suppression effect of ASA
on cognitive dysfunction could be attributed to its ability to target the active sites of the
NLRP3 NACHT domain. Further investigation should be performed in future to deeply
investigate the inhibitory activity of ASA toward the NLRP3 protein which would highlight
ASA as a possible drug for cognitive dysfunction.
5. Conclusions
In the present study, we showed that alcohol intake either alone or in combination
with ATOR caused changes in the biochemical, immunohistochemical and histological
parameters of brain tissue. Our study revealed that administration of alcohol either alone
or in combination with ATOR caused an upregulation of NLRP3/IL1B inflammasome and
its epigenetic regulator, miRNA155, suggesting a key role in neuroinflammation and neurodegeneration. The histological and morphometric analysis indicated neuronal and glial
cell damage as well as aggregations of microglial cells in brain tissue. On the other hand,
ASA administration caused a significant downregulation of the miRNA155/NLRP3/IL1B
inflammasome pathway. The protective effect of ASA was confirmed by histopathological,
morphological and immunohistochemistry studies which revealed a decrease in neuronal damage and diminished microglial cell infiltration in brain tissue with a decrease
in caspase-8 immunoreaction in neurons and glial cells. Finally, our molecular modelling
study indicated the ability of ASA to bind to the binding pockets of the NLRP3 NACHT
domain with high binding scores. Collectively, our findings demonstrated that ASA administration has beneficial and protective effects on cognitive function. Accordingly, we
hypothesize that the administration of ASA to patients with alcoholism and/or long-term
ATOR treatment could effectively attenuate the progression of cognitive impairment.
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